Cara Therapeutics (CARA)

• Market cap: $23.2M
• 1 day: 3.35%
• 5 days: 66.38%
• 1 month: 38.56%
• 3 months: 39.93%
• 6 months: 71.37%
• Year to date: -44.12%
• 1 year: -30.34%
• 5 years: -97.48%
• 10 years: -95.77%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.

Employees: 55

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

7.82% less ownership

Funds ownership: 32.48% [Q2] → 24.66% (-7.82%) [Q3]

9% less capital invested

Capital invested by funds: $4.58M [Q2] → $4.15M (-$430K) [Q3]

14% less funds holding

Funds holding: 81 [Q2] → 70 (-11) [Q3]

61% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 18

85% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 33